Skip to main content

Table 2 Median densities of various immune marker–expressing cells in NSCLCs from patients who received neoadjuvant chemotherapy (NCT) or did not receive NCT (non-NCT) (N = 112)

From: Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Markers

non-NCT (n = 61)

NCT (n = 51)

P a

Median Cell Density (cells/mm2)

 

Panel 1

 MCs (AE1/AE3+)

3559.79

3269.35

0.615

 MCs PD-L1+

34.37

574.58

0.022

 CD3+

903.21

1501.99

0.021

 CD3 + CD4+

671.00

1031.88

0.040

 CD3 + CD8+

156.38

276.08

0.588

 CD68+

298.80

609.36

0.059

 CD68 + PD-L1+

194.46

307.32

0.122

Panel 2

 MCs (AE1/AE3+)

3536.02

2970.70

0.157

 CD45RO+

668.75

1180.26

0.290

 CD45RO + CD57 + granzyme B−

679.09

965.58

0.147

 CD45RO + PD-1+

153.73

443.04

< 0.001

 CD45RO + FOXP3+

5.38

8.37

0.427

 CD57 + granzymeB+

6.87

20.32

< 0.001

 PD-1+

336.02

795.21

< 0.001

  1. MC malignant cells
  2. aMann Whitney U test